gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Cyclin-dependent kinase inhibitor 3

Cyclin-Dependent Kinase Inhibitor p21, CdII, Cyclin-Dependent Kinase Inhibitor
The protein encoded by this gene belongs to the dual specificity protein phosphatase family. It was identified as a cyclin-dependent kinase inhibitor, and has been shown to interact with, and dephosphorylate CDK2 kinase, thus prevent the activation of CDK2 kinase. This gene was reported to be deleted, mutated, or overexpressed in several kinds of cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2008] (from NCBI)
Top mentioned proteins: PCNA, p21, p53, CAN, V1a
Papers on Cyclin-Dependent Kinase Inhibitor p21
Structural optimization of non-nucleoside DNA methyltransferase inhibitor as anti-cancer agent.
Su et al., Cleveland, United States. In Bioorg Med Chem Lett, Feb 2016
Using a high-throughput PCR-based site specific chromatin condensation assay, we identified a compound that reactivated Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) in myeloma cells and suppressed expression of DNMT1 from a library of 5120 chemically diverse small molecules.
Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21.
Merani et al., Sacramento, United States. In Aids, Jan 2016
Furthermore, atorvastatin upregulated the cyclin-dependent kinase inhibitor p21, which is also known as cip-1 and waf-1, in the CD4 T cells.
Evodiamine inhibits the proliferation of leukemia cell line K562 by regulating peroxisome proliferators-activated receptor gamma (PPARγ) pathway.
Liu et al., Rongcheng, China. In J Recept Signal Transduct Res, Jan 2016
In addition, GW9662 and PPARγ-siRNA pretreatment also significantly attenuated the downregulation of the cell cycle control protein cyclin D1 and the upregulation of cyclin-dependent kinase inhibitor p21 induced by evodiamine.
Promoter-associated endogenous and exogenous small RNAs suppress human bladder cancer cell metastasis by activating p21 (CIP1/WAF1) expression.
Ye et al., Wuhan, China. In Tumour Biol, Jan 2016
The cyclin-dependent kinase inhibitor p21 (CIP1/WAF1) (p21) has also been shown to suppress epithelial-mesenchymal transition (EMT) which plays a crucial role in the early stage of tumor metastases and invasiveness.
Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
O'Dwyer et al., Philadelphia, United States. In Jama Oncol, Jan 2016
Importance: Palbociclib (PD0332991) is a newly developed drug that received breakthrough designation and recent US Food and Drug Administration approval in combination with endocrine therapy in the treatment of hormone receptor positive, ERBB2-negative (formerly HER2 or HER2/neu) breast cancer in the first-line metastatic setting.
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Berger et al., Columbus, United States. In Ann Pharmacother, Nov 2015
OBJECTIVE: To review palbociclib, a novel small-molecule inhibitor of cyclin-dependent kinases 4 and 6, and its current place in therapy for the treatment of hormone receptor (HMR)-positive, human epidermal growth factor receptor 2 (Her2)-negative advanced breast cancer.
MytiLec, a Mussel R-Type Lectin, Interacts with Surface Glycan Gb3 on Burkitt's Lymphoma Cells to Trigger Apoptosis through Multiple Pathways.
Ozeki et al., Yokohama, Japan. In Mar Drugs, 2014
Experiments using the specific MEK inhibitor U0126 showed that MytiLec-induced phosphorylation of the MEK-ERK pathway up-regulated expression of the cyclin-dependent kinase inhibitor p21, leading to cell cycle arrest and TNF-α production.
DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier.
Nussenzweig et al., Bethesda, United States. In Nature, 2014
Indeed, we show that restriction-enzyme-induced double-strand breaks are sufficient to induce differentiation of MLL-AF9 blasts, which requires cyclin-dependent kinase inhibitor p21(Cip1) (Cdkn1a) activity.
The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells.
Hase et al., Tokyo, Japan. In Nat Immunol, 2014
Uhrf1 deficiency resulted in derepression of the gene (Cdkn1a) that encodes the cyclin-dependent kinase inhibitor p21 due to hypomethylation of its promoter region, which resulted in cell-cycle arrest of Treg cells.
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
Grant et al., Richmond, United States. In Expert Opin Investig Drugs, 2013
INTRODUCTION: Cyclin-dependent kinases (CDKs) regulate cell cycle progression.
Cyclin-dependent kinase inhibitor p21 controls adult neural stem cell expansion by regulating Sox2 gene expression.
Fariñas et al., Valencia, Spain. In Cell Stem Cell, 2013
Elimination of the cyclin-dependent kinase inhibitor 1A (p21) leads to premature exhaustion of the subependymal NSC pool, suggesting a relationship between cell cycle control and long-term self-renewal, but the molecular mechanisms underlying NSC maintenance by p21 remain unexplored.
Cyclin-dependent kinase inhibitor p21(Waf1): contemporary view on its role in senescence and oncogenesis.
Pospelova et al., Saint Petersburg, Russia. In Biochemistry (mosc), 2012
p21(Waf1) was identified as a protein suppressing cyclin E/A-CDK2 activity and was originally considered as a negative regulator of the cell cycle and a tumor suppressor.
Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation.
Zheng et al., Hangzhou, China. In Biochem Biophys Res Commun, 2012
These results suggest that CDKN3 acts as an oncogene in human hepatocellular carcinoma and antagonism of CDKN3 may be of interest for the treatment of HCC.
The hallmarks of CDKN1C (p57, KIP2) in cancer.
Joseph et al., Stockholm, Sweden. In Biochim Biophys Acta, 2011
Cyclin-dependent kinase inhibitor 1C CDKN1C (p57(KIP2)) regulates several hallmarks of cancer, including apoptosis, cell invasion and metastasis, tumor differentiation and angiogenesis.
Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation.
Jiang et al., Beijing, China. In Cell Prolif, 2011
analysis of CDKN3 cell cycle networks and the molecular mechanism of non-malignancy associated hepatitis/cirrhosis and HCC transformation
High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer.
Sun et al., Nanjing, China. In Int J Cancer, 2010
IKKalpha, IKKbeta, RANK, Maspin, c-FLIP, Cip2 and cyclinD1 were found to show significant differences between hepatocellular tumor tissue and its corresponding adjacent tissue.
Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.
Spiegel et al., Richmond, United States. In Science, 2009
SphK2 associated with HDAC1 and HDAC2 in repressor complexes and was selectively enriched at the promoters of the genes encoding the cyclin-dependent kinase inhibitor p21 or the transcriptional regulator c-fos, where it enhanced local histone H3 acetylation and transcription.
p21 in cancer: intricate networks and multiple activities.
Dutta et al., Charlottesville, United States. In Nat Rev Cancer, 2009
The cyclin-dependent kinase inhibitor p21 (also known as p21WAF1/Cip1) promotes cell cycle arrest in response to many stimuli.
KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction.
Taya et al., Tokyo, Japan. In Biochem Biophys Res Commun, 2007
the reduction of KAP1 levels promotes p53-dependent p21 induction and inhibits cell proliferation in actinomycin D-treated cells.
Transcriptional repression activity of PAX3 is modulated by competition between corepressor KAP1 and heterochromatin protein 1.
Yang et al., T'ai-chung-shih, Taiwan. In Biochem Biophys Res Commun, 2006
Pax3 represses transcription through a novel mechanism involving competition between corepressor KAP1 and the heterochromatin-binding protein HP1gamma
share on facebooktweetadd +1mail to friends